1. Home
  2. MAIA vs GNSS Comparison

MAIA vs GNSS Comparison

Compare MAIA & GNSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • GNSS
  • Stock Information
  • Founded
  • MAIA 2018
  • GNSS 1992
  • Country
  • MAIA United States
  • GNSS United States
  • Employees
  • MAIA N/A
  • GNSS N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • GNSS Consumer Electronics/Appliances
  • Sector
  • MAIA Health Care
  • GNSS Consumer Staples
  • Exchange
  • MAIA Nasdaq
  • GNSS Nasdaq
  • Market Cap
  • MAIA 46.7M
  • GNSS 78.1M
  • IPO Year
  • MAIA 2022
  • GNSS N/A
  • Fundamental
  • Price
  • MAIA $1.88
  • GNSS $1.96
  • Analyst Decision
  • MAIA
  • GNSS Strong Buy
  • Analyst Count
  • MAIA 0
  • GNSS 3
  • Target Price
  • MAIA N/A
  • GNSS $5.33
  • AVG Volume (30 Days)
  • MAIA 529.1K
  • GNSS 131.5K
  • Earning Date
  • MAIA 08-08-2025
  • GNSS 08-05-2025
  • Dividend Yield
  • MAIA N/A
  • GNSS N/A
  • EPS Growth
  • MAIA N/A
  • GNSS N/A
  • EPS
  • MAIA N/A
  • GNSS N/A
  • Revenue
  • MAIA N/A
  • GNSS $27,780,000.00
  • Revenue This Year
  • MAIA N/A
  • GNSS $91.14
  • Revenue Next Year
  • MAIA N/A
  • GNSS $75.44
  • P/E Ratio
  • MAIA N/A
  • GNSS N/A
  • Revenue Growth
  • MAIA N/A
  • GNSS N/A
  • 52 Week Low
  • MAIA $1.40
  • GNSS $1.46
  • 52 Week High
  • MAIA $4.24
  • GNSS $4.04
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 56.41
  • GNSS 70.78
  • Support Level
  • MAIA $1.80
  • GNSS $1.48
  • Resistance Level
  • MAIA $2.15
  • GNSS $1.85
  • Average True Range (ATR)
  • MAIA 0.13
  • GNSS 0.10
  • MACD
  • MAIA 0.02
  • GNSS 0.05
  • Stochastic Oscillator
  • MAIA 60.00
  • GNSS 98.11

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About GNSS Genasys Inc.

Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.

Share on Social Networks: